山东金城医药集团股份有限公司 2019 年第一季度报告全文 山东金城医药集团股份有限公司 2019 年第一季度报告 2019 年 04 月 1 山东金城医药集团股份有限公司 2019 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证季度报告中财务报表的真实、准确、完整。 2 山东金城医药集团股份有限公司 2019 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 | --- | --- | --- | --- | --- | --- | --- | |-------|--------------|-------|-----------------------------------------------------|------------------|--------- ...

山东金城医药集团股份有限公司 2018 年年度报告全文 山东金城医药集团股份有限公司 2018 年年度报告 2019 年 03 月 1 山东金城医药集团股份有限公司 2018 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计 主管人员)贺东声明：保证年度报告中财务报告的真实、准确、完整。 | --- | --- | --- | --- | |-------------------------------------------------------------------------------|--------------------|--------------------|--------------| | 除下列董事外，其他董事亲自出席了审议本次年报的董事会会议 \n未亲自出席董事姓名 | 未亲自出席董事职务 | 未亲自出席会议原因 | 被委托人姓名 | | 郑庚修 | 董事 | 因公务出 ...

山东金城医药集团股份有限公司 2018 年第三季度报告全文 山东金城医药集团股份有限公司 2018 年第三季度报告 2018 年 10 月 1 山东金城医药集团股份有限公司 2018 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证季度报告中财务报表的真实、准确、完整。 2 山东金城医药集团股份有限公司 2018 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增减 | | --- | --- | --- | --- | --- | | 总资产（元） | 5,106,789,672.06 | 4,903,902,054.08 | | 4.14% | | 归属于上市公司股东的净资产 | 4,000 ...

山东金城医药集团股份有限公司 2018 年半年度报告全文 山东金城医药集团股份有限公司 2018 年半年度报告 2018 年 08 月 1 山东金城医药集团股份有限公司 2018 年半年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证半年度报告内容的 真实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别 和连带的法律责任。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证本半年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成公司对 任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风险认 识，并且应当理解计划、预测与承诺之间的差异。 公司在生产运营和企业管理过程中可能存在行业政策、产品质量、药品研 发、并购项目业绩未达预期、商誉减值等风险，有关风险因素内容详见本报告 中第四节"经营情况讨论与分析"部分。敬请广大投资者注意投资风险。 公司计划不派发现金红利，不送红股，不以公积金转增股本。 2 | 目录 | | ...

山东金城医药集团股份有限公司 2017 年年度报告全文 山东金城医药集团股份有限公司 2017 年年度报告 2018 年 03 月 1 山东金城医药集团股份有限公司 2017 年年度报告全文 第一节 重要提示、目录和释义 公司董事会、监事会及董事、监事、高级管理人员保证年度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或重大遗漏，并承担个别和连 带的法律责任。 公司负责人赵叶青、主管会计工作负责人崔希礼及会计机构负责人(会计主 管人员)孙瑞梅声明：保证年度报告中财务报告的真实、准确、完整。 所有董事均已出席了审议本报告的董事会会议。 本报告中如有涉及未来的计划、业绩预测等方面的内容，均不构成公司对 任何投资者及相关人士的承诺，投资者及相关人士均应对此保持足够的风险认 识，并且应当理解计划、预测与承诺之间的差异。 2017 年，公司以五年发展战略规划为指导，借力内部管控模式升级、外部 资本并购扩张，融合创新，转型发展，公司产业转型升级取得实质性进展，具 有金城特色的医药中间体、原料药、制剂一体化的制药产业链全线贯通并加速 融合。随着公司产业规模的持续扩大，涉及的医药领域增加，风险加大，生产 运营、企业 ...

Financial Performance - The company's operating revenue for 2017 was CNY 2,788,037,100.79, representing a 96.29% increase compared to CNY 1,420,385,019.39 in 2016[16] - The net profit attributable to shareholders for 2017 was CNY 286,304,084.82, up 79.62% from CNY 159,390,211.17 in the previous year[16] - The net profit after deducting non-recurring gains and losses was CNY 280,061,674.75, reflecting a 96.64% increase from CNY 142,426,452.36 in 2016[16] - The total assets at the end of 2017 reached CNY 4,903,902,054.08, a 117.29% increase from CNY 2,256,882,763.76 at the end of 2016[16] - The net assets attributable to shareholders increased by 168.97% to CNY 3,864,326,542.41 from CNY 1,436,723,827.49 in 2016[16] - The basic earnings per share for 2017 was CNY 0.77, a 22.22% increase compared to CNY 0.63 in 2016[16] - The total operating revenue for 2017 was ¥2,788,037,100.79, representing a 96.29% increase from ¥1,420,385,019.39 in 2016[62] - The pharmaceutical manufacturing sector contributed ¥2,018,847,580.00, accounting for 72.41% of total revenue, with a year-on-year growth of 67.19%[62] - The chemical trading sector saw a significant increase in revenue to ¥769,189,520.79, up 261.31% from ¥212,887,343.09 in 2016[62] - The gross profit margin for the pharmaceutical manufacturing sector was 45.60%, with a year-on-year increase of 14.29%[64] Dividend Distribution - The company plans to distribute a cash dividend of CNY 2.00 per 10 shares, based on a total of 393,152,238 shares[5] - The company announced a cash dividend of 2.00 RMB per 10 shares, totaling 78,630,447.60 RMB for the year 2017[128] - The cash dividend accounted for 100% of the total distributable profit of 394,339,781.65 RMB[128] - In 2016, the cash dividend was 1.50 RMB per 10 shares, totaling 58,972,835.70 RMB, which represented 37.00% of the net profit attributable to shareholders[134] - The cash dividends for the past three years have shown an increasing trend, with 2017 seeing the highest distribution[134] Strategic Developments - The company has achieved substantial progress in its strategic transformation and integration of its pharmaceutical industry chain[5] - The company completed the acquisition of Langyi Pharmaceutical in 2017, expanding its business scope into pediatric and immunomodulatory drugs[27] - The company is transitioning from a traditional antibiotic production model to a focus on terminal formulations and specialty drugs, enhancing product development and industry integration[27] - The company aims to leverage the pharmaceutical industry's growth potential by accelerating innovation and pursuing investment and acquisition opportunities[34] - The company established a dual-core management model with new management centers in Beijing and Hangzhou to enhance investment and marketing capabilities[45] - The company completed the acquisition of 100% equity in Beijing Langyi Pharmaceutical Co., Ltd. in early 2017, enhancing its market presence[71] Research and Development - The company’s research and development strategy is supported by national technology centers and emphasizes collaboration for balanced multi-platform development[32] - The R&D capabilities were strengthened, with significant progress in product development, including the approval of new indications for certain antibiotics[48] - In 2017, the company increased R&D investment to ¥149,063,677.92, a year-on-year growth of 150.85%[79] - The number of R&D personnel rose to 416, accounting for 15.00% of total employees[79] Market Expansion - The company achieved over 70% market share for glutathione raw materials in the domestic market in 2017, with substantial international presence as well[27] - Sales of glutathione increased by over 80% year-on-year, reflecting strong market expansion efforts[46] - The company is actively expanding its product offerings and market presence, with several products newly entering the national medical insurance directory[58] - The company is focused on expanding its product offerings and market presence through strategic acquisitions and new product development initiatives[105] Operational Challenges - The company acknowledges potential risks in production operations, management, and market expansion, including policy changes and product quality issues[5] - The company is facing market risks influenced by supply and demand, raw material prices, and national policies, which could impact production and sales[120] - The company has a significant amount of accounts receivable, which may increase as it develops domestic and international markets, posing risks of delayed payments and bad debts[123] Environmental and Social Responsibility - The company has implemented pollution control measures, including two thermal oxidation units with a capacity of 10,000 m³/h and 20,000 m³/h, expected to reduce volatile organic compound emissions by 78 tons annually[179] - The company has established a standardized hazardous waste storage facility to manage solid and hazardous waste according to regulatory requirements[180] - The company actively engaged in social responsibility initiatives, including infrastructure improvements and economic crop planting projects in local communities, benefiting areas such as Liujiacun and Liaowu Village[175] - The company supported health and sports activities by investing CNY 80,000 in local football events and donating sports equipment to primary schools[176] Corporate Governance - The company has committed to protecting the legitimate rights and interests of its shareholders[128] - The company has ensured that all related transactions with Jincheng Pharmaceutical will be conducted fairly and transparently, adhering to market principles[139] - The company’s management has committed to not transferring or managing their shares during the lock-up period, ensuring stability in shareholding[139] - The company has established measures to eliminate any potential competition with its major shareholders if such activities arise[138] Future Outlook - The company plans to enhance brand management and increase brand awareness through a comprehensive brand strategy[112] - The company aims to push for international cooperation and strategic acquisitions to enhance resource allocation and market presence in 2018[114] - The company will implement organizational, model, and strategic changes to improve sales and marketing platforms, aiming for increased market share[114] - The company aims to enhance its strategic project implementation to foster new economic growth points, aligning with its five-year strategic plan[117]

山东金城医药集团股份有限公司 2018 年第一季度报告全文 山东金城医药集团股份有限公司 2018 年第一季度报告 2018 年 04 月 1 山东金城医药集团股份有限公司 2018 年第一季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人孙瑞梅及会计机构负责人(会计主 管人员)贺东声明：保证季度报告中财务报表的真实、准确、完整。 2 山东金城医药集团股份有限公司 2018 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | --- | --- | --- | --- | | 营业总收入（元） | 827,540,955.66 | 572,737,727.44 | 44.49% | | 归属于上市公司股东的净利润（元） | 72,413,142.46 | ...

山东金城医药集团股份有限公司 2017 年第三季度报告全文 山东金城医药集团股份有限公司 2017 年第三季度报告 2017 年 10 月 1 山东金城医药集团股份有限公司 2017 年第三季度报告全文 第一节 重要提示 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人崔希礼及会计机构负责人(会计主 管人员)孙瑞梅声明：保证季度报告中财务报表的真实、准确、完整。 2 山东金城医药集团股份有限公司 2017 年第三季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期末 | 上年度末 | | 本报告期末比上年度末增 | | --- | --- | --- | --- | --- | | | | | | 减 | | 总资产（元） | 4,671,356,303.48 | | 2,256,882,763.76 | 106.98% | | 归属于上市 ...

Financial Performance - The total revenue for the reporting period reached CNY 1,211,114,171.32, an increase of 134.58% compared to the same period last year[24]. - The net profit attributable to shareholders was CNY 125,060,454.75, reflecting a growth of 67.38% year-on-year[24]. - The net profit after deducting non-recurring gains and losses was CNY 121,447,106.38, up by 94.45% from the previous year[24]. - The company's total assets increased by 107.30% to CNY 4,678,537,390.66 compared to the end of the previous year[25]. - The net assets attributable to shareholders rose by 157.00% to CNY 3,692,450,255.95[25]. - The basic earnings per share increased by 20.00% to CNY 0.36[24]. - The net cash flow from operating activities decreased by 59.94% to CNY 51,470,092.27[24]. - The company achieved a total investment of ¥2,231,179,964.02 during the reporting period, marking a substantial increase of 17,249.77% compared to the previous year[74]. - The company reported a total of CNY 1,173,616,933.46 in fixed assets, up from CNY 779,227,773.35, indicating a growth of approximately 50.5%[180]. - The total liabilities amounted to CNY 912,127,374.81, an increase from CNY 752,679,538.65, indicating a rise of about 21.2%[181]. Strategic Transformation and Expansion - The company reported significant progress in its strategic transformation and integration of its pharmaceutical supply chain, including intermediates, active pharmaceutical ingredients, and formulations[4]. - The company is expanding its involvement in various pharmaceutical sectors, including drug formulations, biopharmaceuticals, and health products, increasing its market exposure and associated risks[4]. - The company’s strategic planning is guided by a five-year roadmap aimed at enhancing its competitive position in the pharmaceutical industry[4]. - The company completed a major asset restructuring by acquiring 100% equity of Langyi Pharmaceutical, which was included in the consolidated financial statements from March to June 2017[34]. - The company is actively expanding its product pipeline, with ongoing research in various therapeutic areas including antibiotics and nutritional drugs[61]. - The company has established a "Zibo + Beijing" R&D layout and a "R&D + Capital" model, focusing on the development of biopharmaceuticals, high-end pharmaceutical intermediates, and specialty raw materials[41]. - The company has formed a complete industrial chain from pharmaceutical intermediates to raw materials and terminal preparations through the acquisition of Langyi Pharmaceutical, strengthening its core competitive advantage[49]. Risks and Challenges - The company is facing risks related to industry policy changes, particularly those affecting drug production and sales, which could impact its operations significantly[4]. - Environmental regulations may affect production operations, especially in regions where the company has manufacturing bases, potentially leading to operational disruptions[6]. - The company has expressed concerns regarding the uncertainty of achieving performance commitments from its acquisition targets, which may not meet expected profit forecasts[7]. - The company is navigating risks associated with export tax rebate rates and exchange rate fluctuations, which could affect its export operations and overall performance[9]. - The company has a large amount of accounts receivable, which may continue to increase as domestic and international markets are developed, posing risks of delayed payments and bad debts[8]. - The company is exposed to market risks, including rising raw material prices and competitive pressures in the bidding process for drug procurement, which may affect its production and management costs[107]. - The company faces risks related to the performance of acquired assets, as there is uncertainty whether the promised net profit will be achieved due to industry trends and management capabilities[104]. Research and Development - The company has obtained a total of 6 invention patents during the reporting period, enhancing its technological capabilities[50]. - Research and development expenses increased by 65.95% to ¥40,913,818.39, up from ¥24,654,168.29, as various companies within the group intensified their R&D efforts[67]. - The company is focusing on R&D risk management by establishing a dual-location research and development framework and enhancing its technology innovation capabilities[108]. Corporate Governance and Management - The company has established management centers in Beijing and Hangzhou to enhance production management and product sales[40]. - The company emphasizes talent development and has implemented various programs to attract and cultivate skilled professionals in the pharmaceutical industry[48]. - The company appointed several new executives, including a new Chief Financial Officer, which may influence future strategic directions[171]. - The company has not engaged in any significant related party transactions during the reporting period[126]. Legal and Compliance - The company has not encountered any major litigation or arbitration matters during the reporting period, reflecting a stable legal environment[118]. - The company has a pending lawsuit with Shijiazhuang Baiqi Chemical Co., Ltd. involving a payment of 1.6167 million yuan, of which 1.13 million yuan has been recovered[119]. - The company has received a directive for correction from the China Securities Regulatory Commission regarding accounting treatment errors[121]. Market Position and Competitiveness - The company reported a significant increase in market share and competitiveness in the pharmaceutical sector, contributing to substantial revenue and profit growth in 2017[100]. - The company’s subsidiary, Guangdong Jincheng Jinsuo Pharmaceutical, improved its market position significantly compared to the previous year, leading to a notable increase in both revenue and profitability[100]. - The company is focused on expanding its market presence and enhancing its product portfolio through strategic acquisitions and new product development initiatives[100].

山东金城医药股份有限公司 2017 年第一季度报告全文 山东金城医药股份有限公司 2017 年第一季度报告 山东金城医药股份有限公司 2017 年第一季度报告全文 第一节 重要提示 2017 年 04 月 1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真 实、准确、完整，不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和 连带的法律责任。 所有董事均已出席了审议本次季报的董事会会议。 公司负责人赵叶青、主管会计工作负责人崔希礼及会计机构负责人(会计主 管人员)孙瑞梅声明：保证季度报告中财务报表的真实、准确、完整。 2 山东金城医药股份有限公司 2017 年第一季度报告全文 第二节 公司基本情况 一、主要会计数据和财务指标 公司是否因会计政策变更及会计差错更正等追溯调整或重述以前年度会计数据 □ 是 √ 否 | | 本报告期 | 上年同期 | 本报告期比上年同期增减 | | | --- | --- | --- | --- | --- | | 营业总收入（元） | 572,737,727.44 | 253,623,312.40 | | 125.82% | | 归属于上市公司股东的净利润（元） ...